M
Martin Westphal
Researcher at University of Münster
Publications - 233
Citations - 5704
Martin Westphal is an academic researcher from University of Münster. The author has contributed to research in topics: Septic shock & Vasopressin. The author has an hindex of 38, co-authored 232 publications receiving 5259 citations. Previous affiliations of Martin Westphal include Sapienza University of Rome & Australian National University.
Papers
More filters
Journal ArticleDOI
Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial.
Andrea Morelli,Christian Ertmer,Martin Westphal,Sebastian Rehberg,Tim Kampmeier,Sandra Ligges,Alessandra Orecchioni,Annalia D'Egidio,Fiorella D’Ippoliti,Cristina Raffone,Mario Venditti,Fabio Guarracino,Massimo Girardis,Luigi Tritapepe,Paolo Pietropaoli,Alexander Mebazaa,Mervyn Singer +16 more
TL;DR: Targeted heart rates were achieved in all patients in the esmolol group compared with those in the control group and no clinically relevant differences between groups in other cardiopulmonary variables nor in rescue therapy requirements were found.
Journal ArticleDOI
Hydroxyethyl starches: different products--different effects.
Martin Westphal,Michael F. M. James,Sibylle A. Kozek-Langenecker,Reto Stocker,Bertrand Guidet,Hugo Van Aken +5 more
TL;DR: Differences between HES generations are highlighted, with particular emphasis on the improved safety profile of the third generation products, and the impact of source material on structure and pharmacokinetics is highlighted.
Journal ArticleDOI
Effects of levosimendan on right ventricular afterload in patients with acute respiratory distress syndrome: a pilot study.
Andrea Morelli,Jean-Louis Teboul,Salvatore Maurizio Maggiore,Antoine Vieillard-Baron,Monica Rocco,Giorgio Conti,Andrea De Gaetano,Umberto Picchini,Alessandra Orecchioni,Iacopo Carbone,Luigi Tritapepe,Paolo Pietropaoli,Martin Westphal +12 more
TL;DR: Evidence is provided that levosimendan improves right ventricular performance through pulmonary vasodilator effects in septic patients with ARDS and is able to improve the overall prognosis of patients with sepsis and ARDS.
Journal ArticleDOI
Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study
Andrea Morelli,Christian Ertmer,Sebastian Rehberg,Matthias Lange,Alessandra Orecchioni,Valeria Cecchini,Alessandra Bachetoni,Mariadomenica D'Alessandro,Hugo Van Aken,Paolo Pietropaoli,Martin Westphal +10 more
TL;DR: Evidence is provided that continuous infusion of low-dose terlipressin – when given as first-line vasopressor agent in septic shock – is effective in reversing sepsis-induced arterial hypotension and in reducing norepinephrine requirements.
Journal ArticleDOI
The impact of the glycocalyx on microcirculatory oxygen distribution in critical illness.
TL;DR: Deterioration of the endothelial glycocalyx initiates a breakdown of the vascular barrier in systemic inflammatory response syndrome and sepsis, and preserving this structure in critical illness might be a future therapeutical goal to improve microcirculatory oxygen distribution.